Your browser doesn't support javascript.
loading
Total body fluid is the factor that affects the pharmacokinetics of tolvaptan, and its efficacy, in acute worsening heart failure patients.
Kato, Takahiro; Yasuda, Yoko; Okamoto, Hitomi; Saito, Yuji; Nakano, Yusuke; Matsuura, Katsuhiko; Oonishi, Masafumi; Amano, Tetsuya.
Affiliation
  • Kato T; Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Japan.
  • Yasuda Y; Yamakawa Kids Clinic, Nagoya, Japan.
  • Okamoto H; Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Japan.
  • Saito Y; Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Japan.
  • Nakano Y; Department of Cardiology, Aichi Medical University, Nagakute, Japan.
  • Matsuura K; Pharmaceutical Health Care and Sciences Aichi Gakuin University School of Pharmacy, Nagoya, Japan.
  • Oonishi M; Department of Pharmacy, Aichi Medical University Hospital, Nagakute, Japan.
  • Amano T; Department of Cardiology, Aichi Medical University, Nagakute, Japan.
Pharmacol Res Perspect ; 11(3): e01088, 2023 06.
Article in En | MEDLINE | ID: mdl-37102627
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Fluids / Heart Failure Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pharmacol Res Perspect Year: 2023 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Body Fluids / Heart Failure Type of study: Prognostic_studies Limits: Humans Language: En Journal: Pharmacol Res Perspect Year: 2023 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos